{"product_id":"lonza-business-model-canvas","title":"Lonza Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza Business Model Canvas: Strategic Blueprint for Pharma, Biotech \u0026amp; Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Lonza Group's business model—this in-depth Business Model Canvas exposes how Lonza creates value across pharmaceuticals, biotech and specialty ingredients, aligns key partners and capabilities, and monetizes scale in high-growth markets; ideal for investors, consultants, and founders seeking a ready-to-use, downloadable Word\/Excel template to benchmark strategy and accelerate decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biotech and Pharma Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza forms deep alliances with pharma firms, offering long-term manufacturing capacity and development expertise—by end-2025 Lonza had secured \u0026gt;$4.2B in contracted future sales tied to dedicated lines, sharing development risk and CAPEX with partners. These deals often include dedicated production suites within Lonza sites to guarantee supply security and support a steady pipeline of biologics and small molecules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institution Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with top universities and research centers convert early-stage innovation into industrial products, helping Lonza commercialize advances in synthetic biology and cell therapies; in 2024 Lonza reported ~€2.1bn R\u0026amp;D-related revenues and cited multiple joint projects with ETH Zurich and the University of Cambridge that accelerated two clinical manufacturing platforms to GMP scale. These alliances also supply talent—about 18% of Lonza’s PhD hires in 2023 came directly from partner institutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material and Equipment Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza depends on vendors supplying high-purity chemicals, single-use bioreactors, and specialized consumables—about 40% of COGS in 2024 related to external manufacturing inputs—while strategic supplier partnerships cut lead times by 20% and supported a 15% reduction in solvent waste via co-developed greener processes in 2023, ensuring the quality and safety levels required across pharma and biotech manufacturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Health Authorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLonza engages proactively with regulators like the FDA and EMA to stay compliant with evolving GMP standards, supporting faster approvals for client therapies and new sites; in 2024 Lonza reported regulatory-related capex of CHF 220m tied to facility upgrades and compliance programs.\u003c\/p\u003e\n\u003cp\u003eMaintaining transparent regulator relationships underpins Lonza’s operating license and reputation, helping reduce approval timelines—Lonza cites average client tech-transfer approval time reductions of ~15% after formal regulatory engagement programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 220m 2024 regulatory capex\u003c\/li\u003e\n\u003cli\u003e15% avg reduction in tech-transfer approval time\u003c\/li\u003e\n\u003cli\u003eOngoing FDA and EMA engagement for GMP alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Automation Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with software and AI firms let Lonza roll Industry 4.0 into plants for predictive maintenance, real-time monitoring, and analytics, cutting unplanned downtime by up to 20% and boosting yields; Lonza reported automation investments of ~CHF 150m in 2024 to scale these programs.\u003c\/p\u003e\n\u003cp\u003eBy 2025 these tech alliances target a 5–8% reduction in operational costs and tighter batch consistency across sites, improving on-time release rates and reducing batch failures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 150m automation spend (2024)\u003c\/li\u003e\n\u003cli\u003e~20% less unplanned downtime\u003c\/li\u003e\n\u003cli\u003e5–8% OPEX reduction target by 2025\u003c\/li\u003e\n\u003cli\u003eImproved batch consistency, higher on-time release\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza’s partner engine: \u0026gt;$4.2B pharma, academic talent, supplier scale, CHF370m tech+reg boost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza’s key partners: pharma clients (\u0026gt;$4.2B contracted future sales by end-2025), academic centers (joint GMP platforms; ~18% PhD hires from partners), suppliers (≈40% of COGS; 20% cut in lead times), regulators (CHF 220m regulatory capex 2024; 15% faster tech-transfer), and tech firms (CHF 150m automation 2024; ~20% less downtime; 5–8% OPEX target).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$4.2B contracted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e~18% PhD hires\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuppliers\u003c\/td\u003e\n\u003ctd\u003e≈40% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eCHF 220m capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech\u003c\/td\u003e\n\u003ctd\u003eCHF 150m automation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Lonza Group outlining its 9 BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—reflecting its integrated life-science manufacturing, development services, and specialty chemical operations for pharma, biotech, and industrial clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Lonza Group’s business model with editable cells—ideal for quickly identifying how its CRO\/CDMO services, manufacturing capabilities, and regulatory expertise relieve clients’ R\u0026amp;D and scale-up pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Scale Commercial Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLonza runs high-containment, GMP production plants that scale complex biologic and chemical processes for drug substances and products, keeping sterility across multi-ton batches; in 2024 Lonza reported CHF 5.8bn revenue with Pharma \u0026amp; Biotech ~70% and capex guidance ~CHF 750m for 2025 to expand monoclonal antibody and viral vector capacity, targeting double‑digit CAGR in cell\/gene contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcess Development and Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScientists at Lonza convert lab-scale discoveries into scalable, cost-effective processes by refining chemical synthesis and biological expression systems to boost yield and purity, cutting production costs—Lonza reported a 6% process-efficiency gain in 2024, supporting CHF 4.6bn revenue that year. Continuous process improvement shortens time-to-market for clients; pilot-to-commercial scale timelines fell by 15% on average in 2023–24, reducing drug launch delays and capex needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza performs rigorous testing and documentation across the production cycle to meet global safety standards, with its quality operations supporting over 1,500 regulatory submissions globally in 2024 and keeping batch release failure rates below 0.5%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development in Manufacturing Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLonza spends heavily on platforms like the GS Gene Expression System and modular manufacturing units to boost production efficiency for biologics; R\u0026amp;D capex was about CHF 185m in 2024 and 2025 programs focus on scaling personalized cell and gene therapies to reduce time-to-clinic and cost-per-dose.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCHF 185m R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eGS system enables higher yields, shorter timelines\u003c\/li\u003e\n\u003cli\u003eModular units cut scale-up time by months\u003c\/li\u003e\n\u003cli\u003e2025 focus: commercial-scale cell\/gene therapy platforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain and Logistics Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLonza manages global procurement and distribution of sensitive biologics, including specialized cold-chain logistics that preserved product integrity for 98% of temperature-sensitive shipments in 2024, supporting on-time delivery for 92% of clinical trial milestones.\u003c\/p\u003e\n\u003cp\u003eEfficient logistics reduced time-to-market: in 2024 Lonza reported a 7% cut in end-to-end supply lead time and logistics costs representing ~12% of COGS for its pharma manufacturing segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e98% temperature compliance (2024)\u003c\/li\u003e\n\u003cli\u003e92% on-time clinical deliveries (2024)\u003c\/li\u003e\n\u003cli\u003e7% shorter lead times (2024)\u003c\/li\u003e\n\u003cli\u003eLogistics ≈12% of pharma COGS (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLonza boosts GMP biologics capacity—CHF5.8bn revenue, CHF750m capex for mAb\/viral scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLonza scales complex biologics in GMP plants, reported CHF 5.8bn revenue in 2024 with ~70% from Pharma \u0026amp; Biotech, and capex guidance ~CHF 750m for 2025 to expand mAb and viral vector capacity.\u003c\/p\u003e\n\u003cp\u003eKey ops: process scale‑up (6% efficiency gain 2024), quality\/regulatory (1,500+ submissions; \u0026lt;0.5% batch failures), cold‑chain (98% temp compliance; 92% on‑time clinical delivery).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003e2025 Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eCHF 5.8bn\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma \u0026amp; Biotech %\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCHF 185m\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex guidance\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eCHF 750m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcess efficiency gain\u003c\/td\u003e\n\u003ctd\u003e6%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory submissions\u003c\/td\u003e\n\u003ctd\u003e1,500+\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTemp compliance\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time clinical delivery\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Lonza Group Business Model Canvas—not a sample or mockup—and it matches exactly the file you’ll receive after purchase; upon completion, you’ll instantly download the full, editable document in the same professional format for presentation or analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749684949369,"sku":"lonza-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/lonza-business-model-canvas.png?v=1772216976","url":"https:\/\/growthsharematrix.com\/products\/lonza-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}